Rezultaty - Werner Scheithauer
- Rezultaty 1 - 20 Rezultaty od 54
- Idź do następnej strony
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer od B. Gruenberger, Dietmar Tamandl, Johannes Schueller, Werner Scheithauer, Christoph Zielinski, Friedrich Herbst, Thomas Gruenberger
Wydane 2008Artigo -
10
Mitomycin C in combination with capecitabine or biweeklyhigh-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial od Gabriela Kornek, B. Schuell, Friedrich Laengle, Thomas Gruenberger, M. Penz, K. Karall, D. Depisch, Fritz Lang, Werner Scheithauer
Wydane 2004Artigo -
11
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab‐based treatment response in metastatic colorectal cancer od Gerald W. Prager, Kira Braemswig, Alexandra Martel, Matthias Unseld, Georg Heinze, Thomas Brodowicz, Werner Scheithauer, Gabriela Kornek, Christoph Zielinski
Wydane 2014Artigo -
12
Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study od Boris Dickmann, Jonas Ahlbrecht, Cihan Ay, Daniela Dunkler, J. Thaler, Werner Scheithauer, Peter Quehenberger, C. C. Zielinski, Ingrid Pabinger
Wydane 2013Artigo -
13
Thrombosis risk and survival in cancer patients with elevated C‐reactive protein od R. Kanz, Thomas Vukovich, Rainer Vormittag, Daniela Dunkler, Cihan Ay, J. Thaler, Johanna Haselböck, Werner Scheithauer, Christoph Zielinski, Ingrid Pabinger
Wydane 2010Artigo -
14
-
15
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemothera... od Hans‐Joachim Schmoll, Burghardt Wittig, Dirk Arnold, Jorge Riera‐Knorrenschild, D. Nitsche, Hendrik Kroening, Frank Mayer, Johannes Andel, Reinhard Ziebermayr, Werner Scheithauer
Wydane 2014Artigo -
16
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results od J Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Karen Rittweger, Frank Gilberg, Leonard B. Saltz
Wydane 2011Artigo -
17
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of... od Chris Twelves, Werner Scheithauer, J. McKendrick, Jean‐François Seitz, Guy van Hazel, A. Wong, Eduardo Díaz‐Rubio, Frank Gilberg, J Cassidy
Wydane 2011Artigo -
18
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma od H. Ulrich-Pur, Markus Raderer, Gabriela Kornek, B. Schüll, Katharina Schmid, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Fritz Lang, Werner Scheithauer
Wydane 2003Artigo -
19
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial od Werner Scheithauer, B. Schüll, H. Ulrich-Pur, Katharina Schmid, Markus Raderer, K. Haider, W. Kwasny, D. Depisch, Bruno Schneeweiß, Friedrich Lang, Gabriela Kornek
Wydane 2002Artigo -
20
Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors od Irene Virgolini, Markus Raderer, Amir Kurtaran, P. Angelberger, S. Banyai, Qiong Yang, Shuren Li, Martin Banyai, Johann Pidlich, Bruno Niederle, Werner Scheithauer, Peter Valent
Wydane 1994Artigo
Narzędzie wyszukiwania:
Podobne hasła
Internal medicine
Medicine
Cancer
Oncology
Colorectal cancer
Chemotherapy
Surgery
Gastroenterology
Confidence interval
Hazard ratio
Capecitabine
Clinical endpoint
Gemcitabine
Fluorouracil
Pancreatic cancer
Randomized controlled trial
Bevacizumab
Environmental health
Oxaliplatin
Population
Cetuximab
Clinical trial
Irinotecan
Folinic acid
Pathology
Neutropenia
Regimen
Adverse effect
FOLFIRI
Intensive care medicine